

Daiichi Sankyo starts trial for mRNA vaccine as booster dose in Japan

31 January 2022 | News

DS-5670 is an mRNA vaccine against COVID-19 using a novel nucleic acid delivery technology discovered by Daiichi Sankyo

Daiichi Sankyo has initiated a trial in Japan to investigate a booster dose of DS-5670, an mRNA vaccine against COVID-19. The trial is being conducted as a phase 1/2/3 study to evaluate the safety and efficacy of DS-5670 in healthy Japanese adults, including an elderly population, who completed initial vaccination (1st and 2nd shots) against COVID-19 with vaccines approved in Japan after at least 6 months following last vaccination.

The first part of the study will determine the recommended booster dose of DS-5670 followed by a controlled study in 4,500 adults comparing DS-5670 to other vaccines approved in Japan.

The current rapid spread of the Omicron variant of SARS-CoV-2 has imposed an urgent need to develop a booster vaccination program in countries around the world.

As a Japanese pharmaceutical company with specialty in developing vaccines, Daiichi Sankyo is giving special priority to tackling this task and striving to help restore safety and security in society through control of the COVID-19 pandemic, which it hopes to achieve by pursuing the development and commercialization of DS-5670 in Japan during 2022.